Navigation Links
Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of,Blindness in Premature Infants

cts, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, the Company may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than the Company, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Contact

Investor Relations International
Haris Tajyar, 818-382-9702
htajyar@irintl.com


'"/>




Page: 1 2 3

Related medicine technology :

1. Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference
2. Insmed Announces Promising Results From IPLEX Phase II Myotonic Muscular Dystrophy Clinical Study
3. Insmed Releases Positive Results from Iplex Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
6. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
7. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
8. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
9. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
10. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
11. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes

Post Your Comments:
(Date:12/2/2009)..., Dec. 2 TeamHealth Teleradiology ...ion,s largest provider of hospital-based clinical ... to provide teleradiology services for two groups ... signed with UpState Carolina Radiology located in...ology to provide services for the following four h...
(Date:12/2/2009)... Sweden, December 2 DermaGen AB - ... wound healing company "Pergamum" -,today announce...from a,clinical Phase I/IIa study. DermaGen AB is ...atment for atopic dermatitis. Atopic dermatitis is...n and the skin,s weakened barrier,function make pa...
(Date:12/2/2009)... Keryx Biopharmaceuticals....S. Food and Drug Administration (FDA) has granted... the Company,s novel, potentially first-in-class, ...ositide 3-kinase (PI3K)/Akt pathway, for the treat..., The Fast Track program of the FDA is designed ...
Breaking Medicine Technology:TeamHealth Teleradiology Announces New Contracts in South Carolina and Illinois 2Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 2Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 3Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 4Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 2Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 3Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 4Aegis Living Chosen as Best Retirement Facility in 2009 Best of 425 magazine 55950 1Aegis Living Chosen as Best Retirement Facility in 2009 Best of 425 magazine 55950 2Video 3A Renowned Health Expert Dra Aliza Teams Up With Baby Looney Tunes To Promote Healthy Happy Babies 55945 1Video 3A Renowned Health Expert Dra Aliza Teams Up With Baby Looney Tunes To Promote Healthy Happy Babies 55945 2Video 3A Renowned Health Expert Dra Aliza Teams Up With Baby Looney Tunes To Promote Healthy Happy Babies 55945 3Video 3A Renowned Health Expert Dra Aliza Teams Up With Baby Looney Tunes To Promote Healthy Happy Babies 55945 4United Therapeutics Corporation Announces Stock Split To Be Effected as a Stock Dividend 13786 1United Therapeutics Corporation Announces Stock Split To Be Effected as a Stock Dividend 13786 2
...-Apr 3, 2007 - Repros,Therapeutics Inc. (NasdaqGM:...udy of Proellex(TM), an oral drug being developed ...y suggests that,treatment with Proellex results in... symptoms associated with uterine,fibroids and is ...ts , This 12 week, double-blind study compared two...
..., 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc...second multi-center Phase 2 trial of GVAX,immunoth...ng doses,of the immunotherapy in 80 patients with ...C). Additional follow-up of,the 22 patients who re...mployed in the company,s ongoing Phase 3 program i...
Other Medicine Technology:Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 2Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 3
(Date:12/2/2009)... 2 In response to a pr...afety Now ," an initiative from the U.S. Anti-Do...ouncil for Responsible Nutrition (CRN), the leadin...ement industry, issued the following statement: ,... CEO: ,, "We share the concerns of Travis Tyg...
(Date:12/2/2009)...vanced cases, study finds , , WEDNESDAY,...s, survival rates for advanced lung cancer patient...ew study has found. , Researchers analyzed data...e 4 non-small cell lung cancer (NSCLC) between 199.... National Cancer Institute,s Surveillance, Epidem...
(Date:12/2/2009)...e remains unclear, researchers say , , W...suggests that enzyme replacement therapy can make ...ry disease, a rare illness that affects the kidney... linked to the lack of an enzyme that helps metabo...cause it boosts the risk for a stroke, heart attac...
(Date:12/2/2009)...., Dec. 2 Researchers f...n blood cancer research at the annual American Soc... December 4-8, 2009. ,, Throughout the ASH con... experts, including Chief Medical Officer Barton K...t Services Hildy Dillon, and Vice President, Resea...
(Date:12/2/2009)... federal government ends nine months of obstructio...Newswire-USNewswire/ -- More than 2,300 healthcare...lities across Southern California will soon vote o...ealthcare Workers (NUHW). ,, A majority of the ...but SEIU delayed the election by filing frivolous ...
Breaking Medicine News(10 mins):Health News:CRN Responds to 'Supplement Safety Now' Initiative 2Health News:CRN Responds to 'Supplement Safety Now' Initiative 3Health News:Gains Made in Lung Cancer Survival 2Health News:Labor Board OKs 2,300 Kaiser Professionals to Quit SEIU and Join National Union of Healthcare Workers 2
...decrease in health care and compensation benefits,...he economy, employers are managing to maintain a b... Employee Benefits Survey released today by,the So...sing more employers to adjust health care and fina...
... York, June 22). The drug tPA is the most effectiv...s, but its safety is limited to use within the fir...ter that, tPA may cause dangerous bleeding in the ...LICR) and the University of Michigan Medical Schoo...
...men are struggling with the health fallout caused ...(HealthDay News) -- Most women don,t need a survey... often sleep-deprived and feel too sluggish to mak...t most -- women acknowledge that they just don,t g...
... residents in Central U.S. recover, others are pre...oding, WASHINGTON, June 21 The American Red Cros...usands of residents in,states across the Midwest c...i River, residents in Missouri and Illinois,brace ...
...sorts myth from fact when it comes to toeing the l...ne 21 (HealthDay News) -- Summer is here, and many... the beach or in the park. But is that a good thin...rsity,s School of Podiatric Medicine, offers this ...
...HI, India, June 20 The United States,has provided...ernmental,organization Save the Children to assist...s Saiha district of India., Shortages have emerge...ided by the United States, Save the,Children will ...
Other Medicine News:Health News:Despite Economic Downturn, Employee Benefits Remain Stable in 2008 2Health News:Leukemia drug could save lives of stroke patients 2Health News:So Much to Do, So Little Sleep 2Health News:So Much to Do, So Little Sleep 3Health News:The American Red Cross Urges Safety in States Affected by Flooding 2Health News:The American Red Cross Urges Safety in States Affected by Flooding 3Health News:Get in Step With Summer Foot Care 2Health News:Get in Step With Summer Foot Care 3
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
Medicine Products: